# A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

> **NCT02039063** · PHASE1,PHASE2 · COMPLETED · sponsor: **EA Pharma Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** E6011 2 mg/kg
- **DRUG:** E6011 5 mg/kg
- **DRUG:** E6011 10 mg/kg
- **DRUG:** E6011 15 mg/kg

## Key facts

- **NCT ID:** NCT02039063
- **Lead sponsor:** EA Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-05
- **Primary completion:** 2017-01-06
- **Final completion:** 2017-11-27
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039063, "A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02039063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*